Halozyme Therapeutics (NASDAQ:HALO) Upgraded at Zacks Research

Zacks Research upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2026 earnings at $1.24 EPS.

HALO has been the topic of a number of other reports. Morgan Stanley boosted their price objective on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. Benchmark cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 7th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price objective on the stock. Finally, Leerink Partners cut Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus price target of $67.11.

Halozyme Therapeutics Stock Performance

HALO opened at $73.40 on Tuesday. The stock has a market cap of $8.59 billion, a PE ratio of 16.80, a P/E/G ratio of 0.41 and a beta of 1.19. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $75.46. The stock’s 50 day simple moving average is $62.35 and its 200-day simple moving average is $59.69.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $54,618,042.36. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,000 shares of company stock worth $6,316,120 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Large investors have recently made changes to their positions in the business. Wealth Preservation Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the first quarter worth $32,000. SVB Wealth LLC bought a new stake in shares of Halozyme Therapeutics during the first quarter worth $33,000. Bessemer Group Inc. grew its holdings in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $29,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $32,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.